Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NATASHA MESINKOVSKA

Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology

NPI
1346415437
CMS profile
771773
Location
MISSION VIEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$179,433.48

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $94,673.08 77
PFIZER INC. $32,518.48 21
SUN PHARMACEUTICAL INDUSTRIES INC. $25,384.51 10
ABBVIE INC. $10,380.31 4
Eli Lilly and Company $7,035.21 12
LEO Pharma Inc. $3,847.48 2
Janssen Pharmaceuticals, Inc $2,220.00 1
E.R. Squibb & Sons, L.L.C. $2,170.00 2
Almirall LLC $800.00 1
Novartis Pharmaceuticals Corporation $233.51 2
Arcutis Biotherapeutics, Inc. $170.90 2

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NATASHA MESINKOVSKA

NPI 1346415437 · CMS profile ID 771773

Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology

MISSION VIEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346415437?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NATASHA MESINKOVSKA, NPI 1346415437, CMS profile ID 771773. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346415437?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NATASHA MESINKOVSKA, NPI 1346415437, CMS profile ID 771773. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346415437?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NATASHA MESINKOVSKA, NPI 1346415437, CMS profile ID 771773, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1346415437?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $179,433.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $1,350.0003/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135234086 CMS
Lilly USA, LLC $3,600.0003/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135283116 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $8,900.0003/22/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1154913316 CMS
Lilly USA, LLC $24.9003/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135175787 CMS
Lilly USA, LLC $28.1403/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135283120 CMS
Lilly USA, LLC $3,600.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135221340 CMS
Lilly USA, LLC $1,350.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135283112 CMS
Novartis Pharmaceuticals Corporation $94.0503/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087132726 CMS
Lilly USA, LLC $3,150.0003/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135175785 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $6,400.0003/02/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1154913318 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.3503/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913320 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $147.3703/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913322 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $59.4103/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913324 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.0403/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913326 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $12.1803/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913328 CMS
Lilly USA, LLC $38.0002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135175783 CMS
Lilly USA, LLC $46.0002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135221331 CMS
Lilly USA, LLC $10.0002/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135221336 CMS
Lilly USA, LLC $50.0002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135238004 CMS
Lilly USA, LLC $42.4602/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135238008 CMS
Lilly USA, LLC $3,150.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135234082 CMS
Lilly USA, LLC $3,600.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135236348 CMS
ABBVIE INC. $230.3102/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105026466 CMS
Arcutis Biotherapeutics, Inc. $140.7002/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121066353 CMS
Lilly USA, LLC $381.8502/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135175775 CMS
Lilly USA, LLC $70.0002/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135221315 CMS
Lilly USA, LLC $280.0102/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135234066 CMS
Lilly USA, LLC $335.7602/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135234071 CMS
Lilly USA, LLC $235.4602/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135234074 CMS
Lilly USA, LLC $243.4502/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135266498 CMS
Lilly USA, LLC $9.8902/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135271686 CMS
Lilly USA, LLC $1,013.6802/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135271691 CMS
Lilly USA, LLC $3,600.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135175781 CMS
Lilly USA, LLC $1,350.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135266510 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $6,300.00 2
PY2021 $24,878.21 6
PY2022 $52,413.87 28
PY2023 $110,563.17 77
PY2024 $179,433.48 134
PY2025 $125,350.18 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $324,762.12 50
PY2024 Recipient $7,800.00 3
PY2024 Principal investigator $395,157.43 46
PY2023 Recipient $11,620.00 5
PY2023 Principal investigator $346,471.16 52
PY2022 Recipient $7,420.00 5
PY2022 Principal investigator $221,410.66 55
PY2021 Recipient $1,930.00 4
PY2021 Principal investigator $317,748.68 57
PY2020 Recipient $1,925.65 2
PY2020 Principal investigator $1,078,606.80 90
PY2019 Principal investigator $838,362.13 91

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202425041
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,980.00 12/24/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435424
Principal investigator 1 PFIZER INC. $32,192.00 12/19/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228816228
Principal investigator 1 ABBVIE INC. $813.12 12/18/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202425029
Principal investigator 1 ABBVIE INC. $3,163.23 12/04/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202425017
Principal investigator 1 ABBVIE INC. $2,578.47 11/17/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202425001
Principal investigator 1 ABBVIE INC. $50.16 11/10/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424996
Principal investigator 1 ABBVIE INC. $1,528.48 11/04/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424981
Principal investigator 1 SANOFI US SERVICES INC. $3,630.00 11/04/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226148492
Principal investigator 1 Eli Lilly and Company $1,250.00 10/27/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187872607
Principal investigator 1 ABBVIE INC. $462.00 10/15/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424927
Principal investigator 1 ABBVIE INC. $6,979.08 10/09/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424909
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,563.09 10/08/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435421
Principal investigator 1 ABBVIE INC. $6,370.97 09/04/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424876
Principal investigator 1 ABBVIE INC. $2,336.32 09/03/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424871
Principal investigator 1 ABBVIE INC. $9,727.94 08/06/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424852
Principal investigator 1 ABBVIE INC. $1,320.00 07/29/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424827
Principal investigator 1 ABBVIE INC. $3,842.00 07/29/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424830
Principal investigator 1 SANOFI US SERVICES INC. $3,615.39 07/28/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226148459
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $792.00 07/28/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435407
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $792.00 07/28/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435411
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $792.00 07/28/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435418
Principal investigator 1 ABBVIE INC. $1,721.92 07/16/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424800
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $17,947.25 07/15/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435403
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,320.00 07/11/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435399
Principal investigator 1 ABBVIE INC. $1,356.24 07/02/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424740
Principal investigator 1 ABBVIE INC. $1,791.79 07/02/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424745
Principal investigator 1 ABBVIE INC. $3,450.48 07/02/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424749
Principal investigator 1 ABBVIE INC. $813.12 06/05/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424722
Principal investigator 1 ABBVIE INC. $9,851.24 06/03/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424714
Principal investigator 1 ABBVIE INC. $1,320.00 05/22/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424710
Principal investigator 1 ABBVIE INC. $1,320.00 05/15/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424707
Principal investigator 1 ABBVIE INC. $9,144.50 05/07/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424683
Principal investigator 1 ABBVIE INC. $1,356.24 05/06/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424671
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,332.36 04/11/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435396
Principal investigator 1 ABBVIE INC. $12,512.95 04/03/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424658
Principal investigator 1 ABBVIE INC. $2,421.12 04/03/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424662
Principal investigator 1 Eli Lilly and Company $1,169.07 03/10/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187877789
Principal investigator 1 SANOFI US SERVICES INC. $3,093.25 03/10/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226148425
Principal investigator 1 ABBVIE INC. $6,325.16 03/07/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424647
Principal investigator 1 ABBVIE INC. $615.12 03/06/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202424640
Principal investigator 1 ABBVIE INC. $613.08 03/06/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424643
Principal investigator 1 SANOFI US SERVICES INC. $10,412.97 02/18/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226148406
Principal investigator 1 ABBVIE INC. $26,279.19 02/06/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424627
Principal investigator 1 ABBVIE INC. $1,591.92 02/05/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202424616
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,755.78 01/22/2025 Non-covered Recipient Entity
University of Irvine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435392
Principal investigator 1 PFIZER INC. $52,951.23 01/21/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
CHARACTERIZING SKIN MICROBIOME CHANGE IN ATOPIC DERMATITIS PLATIENTS AFTER TARGETED TOPICAL TREATMENT USING CRISABOROLE OINTMENT No dispute reported 06/30/2026 1228828107
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,494.38 01/17/2025 Non-covered Recipient Entity
Uci Health Fountain Valley
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235992797
Principal investigator 1 ABBVIE INC. $1,469.11 01/13/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202424611
Principal investigator 1 ABBVIE INC. $25.00 01/02/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202424604